- Leading Japanese provider of therapies for eye diseases with global sales of 162 billion yen (Euro 1.16 billion1) in over 50 countries
- European sales to grow from 9% in fiscal 2014 to 15% of global sales in 2017
- New HQ in Geneva to lead European commercial network, manufacturing and R&D activities
September 2, 2015 , Osaka, Japan and Geneva, Switzerland – Santen Pharmaceutical Co., Ltd (Osaka, Japan, Tokyo Stock Exchange Code 4536) – Santen – today officially inaugurated its new European Head Quarters in Geneva, Switzerland. The company was founded in Japan in 1890 and is a speciality pharmaceutical company dedicated to providing innovative therapies for patients suffering from eye diseases. In fiscal year ending 31 March 2015, it had global sales of 162 billion yen (1.16 billion euro) across more than 50 countries. The company has been present in Europe since the 1990s, and today employs over 600 professionals across the continent. The new European HQ in Geneva, Switzerland, will lead the growing commercial network, manufacturing and R&D activities.
Mr Akira Kurokawa, President and CEO of Santen, said: “Our ambition for 2020 is to become a specialised company with a global presence and overseas sales to represent 40% -50% of our revenues. This new European HQ is a key element in that strategy. Switzerland and Geneva in particular offers an outstanding location from which to expand our commercial footprint, and to benefit from the life-science expertise and networks established here.”
Mr Shigeo Taniuchi, Head of Santen Europe, commented: “We are excited to be located in this vibrantly international city of Geneva which provides such a welcoming ecosystem for professional and personal development. I look forward to engaging with all our new key stakeholders across industry, research and academia.”
Mr Pierre Maudet, Conseiller d’Etat, République et Canton de Genève, stated: “I am delighted by the installation in Geneva of the European Headquarters of Santen Pharmaceutical. Innovation lies at the heart of the development policy of the Canton of Geneva where businesses, start-ups, R&D, academia and global governance create a specially dynamic and productive ecosystem. The arrival of a world leader in ophthalmology enriches the local community of life sciences.”
The new office was inaugurated today at an event hosted by Mr Akira Kurokawa, President and CEO, with an address by Mr Pierre Maudet, minister in charge of the economy and security for the Canton of Geneva. The guests included representatives from government, the diplomatic community, economic and life science associations, research and academic institutions.